Drug Profile


Alternative Names: R 639; RO 67-0565; SPP 301

Latest Information Update: 26 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Speedel Pharmaceuticals
  • Class Cardiovascular therapies; Pyridines; Pyrimidines; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 07 May 2009 No development reported - Phase-II for Diabetic nephropathies in European Union (PO)
  • 09 Jul 2008 Speedel has been acquired by Novartis
  • 19 Jun 2008 Preclinical pharmacodynamics data presented at the 18th European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension (HYP-2008) ,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top